Matthew Dowling, Ph.D., Chief Scientific Officer and Director. Matt completed his graduate work at the Fischell Department of Bioengineering at the University of Maryland (UMD), after completing his undergrad in Chemical Engineering from the University of Notre Dame. At UMD, he was awarded the Fischell Fellowship in Biomedical Engineering for his innovative ideas in drug delivery systems. Matt then co-created gel-e, a novel biomaterial platform, raising several initial grants to develop the technology and to launch Medcura as a corporate entity. Matt was the recipient of the Dean’s Doctoral Research Award from the UMD Clark School of Engineering for his work on chitosan-based self-assembled soft materials for use in wound treatment. He has been the Principal Investigator on $10 million in non-dilutive grant awards to Medcura; these have been used to achieve 5 FDA clearances, 2 Breakthrough Device Designations, 28 issued patents, and 10+ peer-reviewed publications in high-impact journals. Matt’s work has been featured on several US and international media outlets including the BBC TV program, Brave New World with Stephen Hawking.